Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.» Read More
Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."
Movement in a few key sectors could give stocks a much-needed boost.
Ever wonder how these people decide which stock's a buy and which is a sell? Now you know.
Depends on which analyst you believe. Find out who Cramer's siding with.
Following are the day’s biggest winners and losers. Find out why shares of Staples and Honda popped while Nokia and ConAgra dropped.
Scott Richter, portfolio manager of the Fifth Third Disciplined Fund, prescribes two stocks in the pharmaceuticals sector.
To give investors an edge, CNBC asked the market experts for their best trades now.
Mary Jane Matts knows a few things about "up" stocks in a "down" market, and she's sharing a couple of suggestions with CNBC.
The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.
Following are the week’s biggest winners and losers. Find out why shares of Valero and Lehman popped while State Street and Wynn dropped.
Following are the day’s biggest winners and losers. Find out why shares of Smithfield Foods and Compuware popped while Manitowoc and Las Vegas Sands dropped.
Forest Laboratories on Tuesday posted a better-than-expected profit, but shares fell 7.5 percent as the mid-sized drugmaker projected only slightly higher full-year earnings due to expenses to improve its product line.
The recent gyrations in the markets may have scared some investors away, but two leading portfolio managers say there are still plenty of value stocks to be snapped up.
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
Scott Richter has a set of directions for investors in a market that lacks direction: be selective; be defensive; and be very attentive to valuation.
Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.
If or when you watch one of the presidential debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...
So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.
Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.